August 20, 2019

Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis

August 6, 2019

Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019

July 23, 2019

Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study

July 22, 2019

Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study

July 10, 2019

Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation

June 4, 2019

Myovant Sciences to Present at Upcoming June Investor Conferences

May 30, 2019

Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares

May 29, 2019

Myovant Sciences Announces $100 Million Public Offering of Common Shares

May 24, 2019

Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

May 14, 2019

Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids